LONDON: Two vaccine manufacturers say their shots offer protection against Omicron, because British data suggests, it can lead to proportional inpatiently less than the Delta Coronavirus variant, a supportive conclusion in South Africa.
Coronavirus infection has surged in most of the world as a very contagious Omicron variant has spread, triggering new sidewalks in many countries.
However, the officials of the World Health Organization have emphasized, however, that it is too early to draw strong conclusions about virulence.
First of all identified last month in South Africa and Hong Kong, his variant quickly became dominant in the UK, where daily infections had surged more than 100,000.
Preliminary data has indicated omicron more resistant to the vaccine developed before it appears.
But it increases in hospitalization and death in the UK because Omicron holds more gradually, the researchers said.
The Edinburgh University researcher who tracked 22,205 patients infected by Omicron said on Wednesday that the amount needed to be hospitalized was 68% lower than they expected, based on the level in patients with Delta.
Imperial College London researchers said they saw evidence for the past two weeks 40% to 45% reduced risk of hospitalization for delta.
Meanwhile, Astrazeneca said on Thursday that the dose of three types of vaccines Covid-19 offered protection against variants, citing data from the Oxford University Lab study.
This study has not been published in the Peer-Review Medical Journal, indicating the level of antibodies against Omicrons after booster shots are higher than antibodies in people who have been infected and recover naturally from Covid-19.
A few hours earlier, Novavax Inc.
said the initial data showed its vaccine produced an immune response to Omicron.
Two doses, novovax protein-based vaccines are allowed to be used this week by the European Union and WHO regulators.
It has not been approved by the United States.
Global shares extend recent rallies on Thursday while Safe Haven bonds and currencies eased when the market welcomed the signs that the Omicron Covid-19 variant might be less severe than the feared.
British data on hospitalization was supported by a study released on Wednesday by the South African National Institute for NICD (NiCD).
However, NiCD researchers included several warnings.
“It is difficult to unravel the relative contribution of the high levels of previous population immunity versus intrinsic virulence to reduce the severity of the lower disease observed,” they wrote.
The WHO technical advantage in Covid-19, Maria van Kerkhove, also said the UN office did not have enough data to draw strong conclusions.
Data in Omicron is still “messy,” he told the briefing in Geneva on Wednesday.